Analyst Research

Report Title Price
Provider: Reuters Investment Profile
Provider: Thomson Reuters Stock Report
Provider: Ford Investor Services, Inc.
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Regulus Therapeutics Inc Announces Completion of Public Offering

Tuesday, 23 Jul 2013 08:00am EDT 

Regulus Therapeutics Inc announced the completion of an underwritten public offering of 5,175,000 shares of common stock, including 675,000 shares sold pursuant to the full exercise of an option to purchase additional shares previously granted to the underwriters, at a price to the public of $9.50 per share. The gross proceeds to Regulus from this offering were approximately $49.2 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Regulus. Lazard Capital Markets LLC, Cowen and Company, LLC and BMO Capital Markets Corp acted as joint book-running managers for the offering. Needham & Company, LLC and Wedbush PacGrow Life Sciences acted as co-managers. 

Company Quote

0.26 +1.57%
27 Mar 2015